A novel platform for attenuating immune hyperactivity using EXO-CD24 in COVID-19 and beyond

Area of Science:

• Immunology
• Pharmacology
• Biotechnology

Background:

• Cytokine storm is a life-threatening complication in severe COVID-19.
• Existing treatments for cytokine storm have limitations.
• There is a need for targeted anti-inflammatory therapies.

Purpose of the Study:

• To develop and evaluate EXO-CD24, a novel anti-inflammatory drug for COVID-19 cytokine storm.
• To assess the safety and efficacy of EXO-CD24 in preclinical and clinical studies.
• To explore EXO-CD24 as a potential therapeutic platform for other inflammatory diseases.

Main Methods:

• EXO-CD24 was engineered using exosomes and CD24 to inhibit the NF-kB pathway.
• In vitro and in vivo studies were conducted to characterize EXO-CD24.
• A Phase Ib/IIa clinical trial administered escalating doses of inhaled EXO-CD24 to 35 COVID-19 patients.

Main Results:

• EXO-CD24 demonstrated safety with no drug-related adverse events observed in clinical trial participants.
• The drug effectively reduced inflammatory markers and cytokine/chemokine levels.
• EXO-CD24 selectively targets inflammation without interfering with viral clearance.

Conclusions:

• EXO-CD24 represents a potential treatment strategy for suppressing hyper-inflammation in COVID-19 lung injury.
• The drug's mechanism of action suggests broader applicability for cytokine storm-related conditions.
• Further randomized controlled trials are necessary to confirm efficacy and establish its therapeutic role.